Glaukos Co. (NYSE:GKOS) COO Sells $480,350.00 in Stock

Glaukos Co. (NYSE:GKOSGet Free Report) COO Joseph E. Gilliam sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $96.07, for a total value of $480,350.00. Following the sale, the chief operating officer now owns 119,802 shares of the company’s stock, valued at $11,509,378.14. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Glaukos Stock Performance

Shares of GKOS stock opened at $96.42 on Tuesday. The stock’s 50-day moving average is $83.26 and its two-hundred day moving average is $74.99. The firm has a market cap of $4.71 billion, a price-to-earnings ratio of -35.84 and a beta of 1.11. Glaukos Co. has a 1 year low of $44.26 and a 1 year high of $97.24. The company has a debt-to-equity ratio of 0.74, a quick ratio of 5.36 and a current ratio of 5.95.

Institutional Investors Weigh In On Glaukos

Several hedge funds have recently made changes to their positions in the business. Xponance Inc. lifted its position in Glaukos by 4.1% in the fourth quarter. Xponance Inc. now owns 2,879 shares of the medical instruments supplier’s stock valued at $229,000 after purchasing an additional 113 shares during the period. American International Group Inc. lifted its position in shares of Glaukos by 0.6% during the 2nd quarter. American International Group Inc. now owns 25,246 shares of the medical instruments supplier’s stock valued at $1,798,000 after acquiring an additional 145 shares during the period. Corient Private Wealth LLC lifted its position in shares of Glaukos by 0.7% during the 4th quarter. Corient Private Wealth LLC now owns 24,775 shares of the medical instruments supplier’s stock valued at $1,969,000 after acquiring an additional 163 shares during the period. PNC Financial Services Group Inc. lifted its position in shares of Glaukos by 4.8% during the 2nd quarter. PNC Financial Services Group Inc. now owns 4,353 shares of the medical instruments supplier’s stock valued at $310,000 after acquiring an additional 200 shares during the period. Finally, American Century Companies Inc. lifted its position in shares of Glaukos by 3.1% during the 1st quarter. American Century Companies Inc. now owns 6,878 shares of the medical instruments supplier’s stock valued at $339,000 after acquiring an additional 207 shares during the period. Institutional investors and hedge funds own 99.04% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on GKOS. TheStreet lowered Glaukos from a “c-” rating to a “d+” rating in a research report on Friday, November 24th. Morgan Stanley assumed coverage on Glaukos in a report on Monday, December 4th. They issued an “equal weight” rating and a $65.00 price objective on the stock. JPMorgan Chase & Co. upgraded Glaukos from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $66.00 to $91.00 in a research note on Thursday, December 21st. Piper Sandler upped their price target on Glaukos from $90.00 to $105.00 and gave the stock an “overweight” rating in a research note on Friday, December 22nd. Finally, Needham & Company LLC decreased their price target on Glaukos from $89.00 to $83.00 and set a “buy” rating on the stock in a research note on Thursday, November 2nd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $87.30.

Check Out Our Latest Stock Analysis on GKOS

About Glaukos

(Get Free Report)

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.

See Also

Insider Buying and Selling by Quarter for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.